<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_CSU_CHINA skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:CSU CHINA</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><UL class="navigation-bar"><LI><A href="https://2018.igem.org/Team:CSU_CHINA">HOME</A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Description">  Project  </A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Description">Description</A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Design">Design</A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Experiments">Experiments</A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Notebook">Notebook</A></LI></UL><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Demonstrate">  Results  </A></LI><LI class="long"><A href="https://2018.igem.org/Team:CSU_CHINA/Demonstrate">Demonstrate</A></LI><LI class="long"><A href="https://2018.igem.org/Team:CSU_CHINA/Parts">Parts Overview</A></LI><LI class="long"><A href="https://2018.igem.org/Team:CSU_CHINA/Basic_Part">Basic Part</A></LI><LI class="long"><A href="https://2018.igem.org/Team:CSU_CHINA/Composite_Part">Composite Part</A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/InterLab">  Lab  </A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Safety">Safety</A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/InterLab">InterLab</A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Human_Practices">  Human Practices  </A></LI><LI class="long"><A href="https://2018.igem.org/Team:CSU_CHINA/Human_Practices">Human Practices</A></LI><LI class="long"><A href="https://2018.igem.org/Team:CSU_CHINA/Public_Engagement">Education &amp; Engagement</A></LI><LI class="long"><A href="https://2018.igem.org/Team:CSU_CHINA/Collaborations">Collaborations</A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Team">  Team  </A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Team">Team Members</A></LI><LI><A href="https://2018.igem.org/Team:CSU_CHINA/Attributions">Attributions</A></LI></P><DIV class="container"><TITLE> homepage of CSU_CHINA </TITLE><DIV class="container"><CENTER><H1 style="font-size:250%;">
                         Abstract
                </H1></CENTER></DIV><DIV class="block main-text main-text"><P>
The goal of our team is to develop a sensitive system to specifically kill liver cancer cells via genetic circuits, by using the combination of liver cancer-specific promoters and miRNAs.The expression of Gal4-VP16 fusion protein was under the control of liver cancer cells-specific AFP, hTERT or ZEB1-AS1 promoters. The Gal4-VP16 in turn drives the HSV-thymidine kinase (HSV-TK) expression by binding to nine tandem UAS elements in the promoter.
Furthermore, the expression of Gal80, a Gal4 inhibitor, is controlled under a CMV promoter as well as a cluster of miRNA93/miRNA-362-5p/miRNA-221 binding sites at the 3â€™-end. As miRNA93/miRNA-362-5p/miRNA-221 are liver cancer cells-specific miRNAs, the expression of Gal80 is significantly suppressed in the liver cancer cells compared with normal cells.
As a result, the nontoxic ganciclovir is converted by HSV-TK to a cell-killing drug in the liver cancer cells, but not normal cells.</P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>